Inhibition of the Renin Angiotensin System during Autologous Stem Cell Transplant Does Not Impact Time to Engraftment

Anita J. Kumar, Joseph Carver, Noelle V. Frey

Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA.
Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, USA..

DOI: 10.4236/ojbd.2012.24013                

Abstract

Background: The renin angiotensin system RAS modulates hematopoiesis via local effects in the bone marrow. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) may adversely impact hematopoiesis and time to engraftment in patients undergoing stem cell transplant (SCT). Our study assesses whether the use of ACEi or ARBs delays time to engraftment in patients with multiple myeloma undergoing a melphalan based autologous SCT. Methods: A retrospective review of 58 patients who underwent autologous SCT with a melphalan 200 mg/m2 conditioning regimen for multiple myeloma between January 1 and December 31, 2010 was performed. Results: Of 58 evaluable patients, 47 underwent autologous SCT without an ACEi or ARB (control group), and 11 patients were given ACEi or ARBs (treatment group). Mean time to neutrophil engraftment was 11.5 days in the control group, and 11.3 days in treatment group (p = 0.60). Mean time to platelet engraftment in control group was 13.5 days and 15.1 days in treatment group (p = 0.2). There was no statistically significant difference between groups in time to neutropenic fever and length of hospital stay. Conclusion: Our study demonstrates no significant difference in time to engraftment, incidence of neutropenic fever, or length of hospital stay between patients receiving ACEi or ARBS compared to control subjects. We demonstrate that use of low to moderate dose ACEi or ARB does not lead to prolonged time to engraftment and is safe to use in patients undergoing autologous SCT for multiple myeloma.

Keywords

Multiple Myeloma; ACE Inhibitor; Angiotensin Receptor Blocker; Melphalan; Neutropenia

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	I. C. Haznedaroglu and M. A. Ozturk, “Towards the Understanding of the Local Hematopoietic Bone Marrow Renin-Angiotensin System,” The International Journal of Biochemistry & Cell Biology, Vol. 35, No. 6, 2003, pp. 867-880. doi.org/10.1016/S1357-2725(02)00278-9
[2]	D. V. Vlahakos, et al., “Enalapril-Associated Anemia in Renal Transplant Recipients Treated for Hypertension,” American Journal of Kidney Diseases, Vol. 17, No. 2, 1991, pp. 199-205.
[3]	P. J. Conlon, et al., “Losartan in Post-Transplant Erythrocytosis,” Nephrology Dialysis Transplantation, Vol. 11, No. 12, 1996, pp. 2524-2525. doi.org/10.1093/oxfordjournals.ndt.a027238
[4]	C. Hubert, et al., “The Hematopoietic System: A New Niche for the Renin-Angiotensin System,” Nature Clinical Practice. Cardiovascular Medicine, Vol. 3, No. 2, 2006, pp. 80-85. doi.org/10.1038/ncpcardio0449
[5]	J. Walter, “Does Captopril Decrease the Effect of Human Recombinant Erythropoietin in Haemodialysis Patients?” Nephrology Dialysis Transplantation, Vol. 8, No. 12, 1993, p. 1428.
[6]	K. E. Rodgers, et al., “Effect of Angiotensin II on Hematopoietic Progenitor Cell Proliferation,” Stem Cells, Vol. 18, No. 4, 2000, pp. 287-294. doi.org/10.1634/stemcells.18-4-287
[7]	M. Mrug, et al., “Angiotensin II Stimulates Proliferation of Normal Early Erythroid Progenitors,” Journal of Clinical Investigation, Vol. 100, No. 9, 1997, pp. 23102314. doi.org/10.1172/JCI119769
[8]	P. Van der Meer, et al., “Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure,” Circulation, Vol. 112, No. 12, 2005, pp. 1743-1747. doi.org/10.1161/CIRCULATIONAHA.105.549121
[9]	J. Cole, et al., “Lack of Angiotensin II-Facilitated Erythropoiesis Causes Anemia in Angiotensin-Converting Enzyme-Deficient Mice,” Journal of Clinical Investigation, Vol. 106, No. 11, 2000, pp. 1391-1398. doi.org/10.1172/JCI10557
[10]	S. Heringer-Walther, et al., “Angiotensin-(1-7) Stimulates Hematopoietic Progenitor Cells in Vitro and in Vivo,” Haematologica, Vol. 94, No. 6, 2009, pp. 857-860. doi.org/10.3324/haematol.2008.000034
[11]	F. Deshayes and C. Nahmias, “Angiotensin Receptors: A New Role in Cancer?” Trends in Endocrinology & Metabolism, Vol. 16, No. 7, 2005, pp. 293-299. doi.org/10.1016/j.tem.2005.07.009
[12]	V. J. Jokubaitis, et al., “Angiotensin-Converting Enzyme (CD143) Marks Hematopoietic Stem Cells in Human Embryonic, Fetal and Adult Hematopoietic Tissues,” Blood, Vol. 111, No. 8, 2008, pp. 4055-4063. doi.org/10.1182/blood-2007-05-091710
[13]	T. S. Park and E. T. Zambidis, “A Role for the ReninAngiotensin System in Hematopoiesis,” Haematologica, Vol. 94, No. 6, 2009, pp. 745-747. doi.org/10.3324/haematol.2009.006965
[14]	S. Charrier, et al., “Inhibition of Angiotensin I-Converting Enzyme Induces Radioprotection by Preserving Murine Hematopoietic Short-Term Reconstituting Cells,” Blood, Vol. 104, No. 4, 2004, pp. 978-985. doi.org/10.1182/blood-2003-11-3828